Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LAG-3 drug discovery.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LAG-3 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). D1-D2 domains for MHC-II binding studies. |
View LAG-3 Products |
| Gene Delivery | LAG-3 Lentivirus Premade Particles Full-length ORF for stable cell line construction. Ideal for T-cell reporter assays. |
View LAG-3 Products |
| Benchmark Ab | Anti-LAG-3 (Sequence of Relatlimab) Recombinant positive control for blocking assays. |
View LAG-3 Products |
| Validator | LAG-3 siRNA Set For knockdown verification and specificity controls. |
View LAG-3 Products |
| Ligand | HLA-DRB1 (MHC Class II) Recombinant Protein Verified binding partner for blocking/inhibition assays. |
View HLA-DRB1 Products |
| Combination Target | PD-1 (PDCD1) Synergistic checkpoint; essential for co-blockade studies. |
View PD-1 Products |
| Related Target | TIM-3 (HAVCR2) Competing immune checkpoint; alternative resistance pathway. |
View TIM-3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse Preclinical Evaluation | Human/Mouse/Cyno LAG-3 ortholog ECD proteins available with >95% purity; sequence verified by mass spec. |
| Multi-ligand Blocking Validation (MHC-II, FGL1) | Recombinant ligands (MHC-II, FGL1) structurally verified for SPR and ELISA competition assays. |
| Epitope Binning (D1 vs D2 Domain) | Truncated domain variants (D1-Fc, D1-D2-Fc) available for precise epitope mapping. |
| Cell-Based Functional Validation | Lentivirus particles for stable LAG-3 expression in Jurkat or CHO cells; preserves conformation for flow cytometry. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included. |
| False Positives | Validated siRNA included for specificity checks. |
Live LAG-3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The LAG-3 checkpoint inhibitor field has matured rapidly following the FDA approval of Opdualag (Nivolumab + Relatlimab) by Bristol Myers Squibb in 2022 for unresectable or metastatic melanoma. This approval validated LAG-3 as a viable target distinct from PD-1/CTLA-4, cementing combination immunotherapy as the dominant paradigm. As first-generation therapies reach the clinic, the next wave of R&D is targeting optimal affinity tuning to minimize immune-related adverse events while maximizing T-cell reinvigoration in refractory solid tumors. The competitive landscape is now bifurcating: First-generation monoclonal antibodies focus on PD-1 combination blocks, while next-wave innovators (AstraZeneca, MacroGenics, Xencor) are advancing PD-1/LAG-3 bispecifics to achieve synchronized checkpoint blockade with a single molecule. Additionally, soluble LAG-3 (sLAG-3) is emerging as a critical pharmacodynamic biomarker, driving demand for high-sensitivity detection assays.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Combo) | BMS (Relatlimab), Merck (Favezelimab), Regeneron/Sanofi (Fianlimab) | Melanoma, NSCLC, Colorectal Cancer | MHC-II Blocking Assay (Need high-purity D1-domain protein) |
| Bispecific (PD-1/LAG-3) | MacroGenics (Tebotelimab), AstraZeneca (AZD2936), Xencor | Solid Tumors (Broad) | Heterodimer Validation & Cross-reactivity (Need species-matched orthologs) |
| ADC / Immune Agonist | Innate Pharma (TLR8 agonist conjugate), Early Biotech | Treg-depletion, Solid Tumors | Internalization Assay (Need stable LAG-3+ cell lines via Lentivirus) |
| Soluble LAG-3 Detection | Immutep (IMP321), Diagnostics Partners | Biomarker / Prognosis | Standard Calibration Protein (Need unglycosylated vs. native variants) |
| Recombinant Protein / Fusion | Immutep | Breast Cancer, NSCLC | Receptor Activation Assay (Need HEK293 Expressed Glycosylated Proteins) |